DETERRED: PD-L1 blockadE To Evaluate the Safety of Lung CanceR Therapy Using Carboplatin, Paclitaxel, and Radiation CombinEd With MPDL3280A
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms DETERRED
- 18 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Feb 2018 Planned End Date changed from 1 Jan 2020 to 1 Jan 2021.
- 01 Nov 2017 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.